The new test, from Fujirebio Diagnostics, Inc., identifies a sticky brain plaque, known as beta-amyloid, that is a key marker ...

The Food and Drug Administration has cleared Fujirebio Diagnostics’ blood test to diagnose Alzheimer’s disease, the regulator ...

The Lumipulse Alzheimer's blood test is the first of a new generation of tests that may replace brain scans and spinal taps to detect the disease.

The findings show that memory clinics can have “the infrastructure and expertise to safely administer and care for patients ...

Most ARIA cases were asymptomatic and radiographically mild. Treating early Alzheimer's disease patients with lecanemab (Leqembi) was feasible and most patients tolerated the drug well ...

The U.S. Food and Drug Administration said on Friday it had cleared a blood test to diagnose Alzheimer’s disease, making the test the first of its kind to detect the condition.

Leqembi market analysis highlights key dynamics, including growth potential driven by increased Alzheimer's prevalence, advancements in treatments, and innovations in IV dosing. Key player Eisai Co.

More than 80,000 Kentuckians aged 65 and older live with an Alzheimer’s diagnosis, a new report shows. Meet one of them.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 ...

The FDA has approved the first blood test for diagnosing Alzheimer’s disease, which could speed the path to treatment for ...

The FDA said it has issued its first official green light for a blood test to help diagnose Alzheimer’s disease, adding that ...